Study results
Title: Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage.
Meningitis is a rare but potentially life-threatening infection around the surface of the brain. It mostly affects babies, young children, and adolescents.
A bacterium called meningococcus is an important cause of bacterial meningitis.
This study looked at whether immunising teenagers with a Meningitis B (MenB) vaccine could reduce the risk of others getting meningitis across the whole community.
‘Be on the TEAM’ meningitis vaccine study. We are excited to share the first results from the ‘TEAM’ study with you. MenACWY vaccines block throat carriage and will provide herd protection across the community. You can read the results at https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00368-8/fulltext
For information on our AvonCAP study results, please click here.
COVID-19 Mapping and Mitigation in Schools (CoMMinS)
Title: COVID-19 Mapping and Mitigation in Schools.
The University of Bristol collaborated with Public Health England, the Bristol City Council, and local schools, to understand the practical challenges of preventing an outbreak of COVID-19 in schools.
Visit the CoMMinS study website for full details and results.
WHAT’S THE STORY
Title: What's the story? A Sero-epidemiological survey of England in 2019/2020/2021
The Bristol Children’s Vaccine Centre researched a new way of surveying how well protected we are from infectious diseases by collecting blood samples from people who represent different groups across society.
The study was run by Bristol Children’s Vaccine Centre, and the Oxford Vaccine Group (part of the University of Oxford).
Please see our results here.
Harmonie Study
Title: A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants
The Harmonie Study found that Nirsevimab, the monoclonal antibody vaccine, delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting and reinforce its consistent and high efficacy against infant hospitalizations due to RSV.
Data presented at ESPID add to the body of evidence demonstrating nirsevimab’s protection against RSV-related lower respiratory tract disease (LRTD) and confirm its favourable safety profile in multi-country, real-world conditions.
Further information about the study results will be posted here.